Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Atopic Dermatitis/Atopic Eczema | Emerging Therapies | Dupixent (dupilumab) | US | Wave 3 | 2018

Login to access report north_east
Contact sales account_box

Atopic Dermatitis | Emerging Therapies | Dupixent | US is a three-wave series that tracks the introduction of Sanofi/Regeneron’s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent’s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial and use, including anticipated future trends, of Dupixent. We also explore Sanofi/Regeneron’s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.

What you will learn in this content:

  • What are U.S. dermatologists’ awareness of and familiarity with Dupixent, and what are their perceptions of the product?
  • To which patients is Dupixent being prescribed, what are the reasons for prescribing it, and how satisfied are dermatologists with it?
  • What promotional messages and activities are Sanofi and Regeneron using to support Dupixent’s launch?
  • How do prescribers and nonprescribers compare across key metrics?
  • How do the trial and adoption of Dupixent compare with the trial and adoption of other recent product launches for AD?

Methodology: ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.

Key drugs: Dupixent

Key companies: Sanofi, Regeneron

Related reports: Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement – Atopic Dermatitis (US), Access and Reimbursement – Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Asthma – Unmet Need – Unmet Need – Severe Asthma (US/EU)
Several effective anti-inflammatory agents and bronchodilators are available for controlling patients’ mild or moderate asthma. However, despite the availability of LAMAs (e.g., Boehringer…
north_east
Report
Systemic Lupus Erythematosus – Current Treatment – Treatment Algorithms: Claims Data Analysis – Systemic Lupus Erythematosus (US)
Systemic lupus erythematosus (SLE) is an autoimmune disease that affects multiple organ systems of the body. Symptoms range from general malaise to serious renal and CNS manifestations…
north_east
Report
Chronic Kidney Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Kidney Disease (US)
Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises therapies, which are…
north_east
Report
Multiple Sclerosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Multiple Sclerosis (US)
The multiple sclerosis (MS) therapy market comprises more than 20 immunomodulatory disease-modifying therapies (DMTs), and more are in the pipeline. A variety of drug classes each hold a niche…
north_east
Report
Asthma – Access & Reimbursement – Access & Reimbursement – Asthma (US)
The dynamics within the LABA/ICS FDC, LAMA, LABA/LAMA/ICS FDC, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GSK’s…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east